We report a 44-year-old male patient who received a TBI and CY based hematopoietic stem cell transplant (HSCT) from an HLA-identical brother in April 2007. He was diagnosed with Philadelphia chromosome-positive ALL in January 2007, and proceeded to transplant after reaching hematological remission with molecular evidence for minimal residual disease following the first induction cycle. The pretransplant course was complicated by pulmonary mucormycosis requiring surgical and systemic treatment. Considering the history of this life-threatening infectious complication, CsA monotherapy was chosen as initial GVHD prophylaxis. Methylprednisolone (MP) was added on day þ 8 after the appearance of mild cutaneous GVHD. Following the diagnosis of transplant-associated microangiopathy (TAM) in July 2007, the patient was treated with rituximab and a series of plasma separations. Because of incomplete resolution of TAM related signs, CsA was first switched to tacrolimus, and 9 months post transplant, calcineurin inhibitor treatment was discontinued. Thereupon, platelet counts increased above 50 Â 10 6 per l whereas anemia persisted. After development of moderate chronic GVHD, MP was started at 1 mg/kg with subsequent taper, in addition to extracorporeal photopheresis. Because of deterioration of chronic GVHD with severe involvement of the lungs 14 months post transplant, rapamycin 1 mg twice daily was added to the immunosuppressive regimen and MP was again increased to 80 mg daily. Two weeks later, the patient presented with generalized edema, wt gain of 5 kg within the previous 5 days and hypertension of 170/100 mm Hg. The laboratory parameters before onset of rapamycin are shown in Table 1 . Laboratory evaluation 2 weeks after onset of rapamycin revealed typical changes of the parameters of nephrotic syndrome with a serum creatinine of 1.38 mg per 100 ml (Table 1) . Urine analysis revealed a protein/creatinine ratio of 7 g/g and an albumin/creatinine ratio of 5.3 g/g, consistent with rapamycin-induced proteinuria ( Table 1) . Because of low platelet counts, a kidney biopsy was omitted. Rapamycin was discontinued and an angiotensin-converting enzyme (ACE)-inhibitor was initiated. In addition the patient received loop diuretics. GVHD treatment consisted of MP monotherapy at this time. Proteinuria rapidly decreased and signs of nephrotic syndrome disappeared within days ( Figure 1 ). Up to the present, the patient's course is characterized by repeated aggravation of chronic GVHD with predominantly cutaneous involvement. Its treatment has included mycophenolate mofetil, MP, CsA and alemtuzumab. In addition to, a new episode of fungal pneumonia has occurred, besides repeated CMV reactivations. Retrospectively, rapamycin was started when proteinuria was already evident without clinical signs of a nephrotic syndrome. As no kidney biopsy was performed we can only speculate on the cause of initial proteinuria. The laboratory investigations (Table 2 ) revealed the differential diagnosis of a membranous nephropathy or a focal segmental glomerular sclerosis in combination with a calcineurin inhibitor nephropathy, because of selective glomerular-tubular proteinuria in the nephrotic range. Membranous glomerulonephritis (GN) and minimal change GN have been reported to develop in a few patients, because of chronic GVHD of the kidney. 1 Nevertheless, it is possible that chronic GVHD was not the cause of proteinuria in our patient because proteinuria already existed before HSCT. Rapamycin is well known to aggravate proteinuria and in some cases induces nephrotic syndrome in patients after renal transplantation.
2-4 A recent ongoing prospective trial in renal transplant patients revealed that patients with a proteinuria of more than 500 mg switched to rapamycin are prone to an increase in proteinuria and a decline in renal function. 5 The histologic changes induced by rapamycin vary between the different reports. Unspecific changes, but also the induction of various forms of GN such as IgA nephritis, membranous GN, membranoproliferative GN and focal segmental glomerulosclerosis have been described. 2, 3 The causes of rapamycin-induced proteinuria are so far unknown. In experimental studies it was proposed that a decrease of vascular endothelial growth factor and/or an increase in proinflammatory cytokines such as interleukin-6 might be responsible for the pathologies observed. [6] [7] [8] Rapamycininduced proteinuria is not only observed in renal transplant patients, but was recently shown also in long-term cardiac transplant patients. 9 In patients after SCT data on the clinical efficacy of rapamycin is scarce. Jurado et al. 10 provide evidence that rapamycin is beneficial in the treatment of refractory chronic GVHD, whereas others found rapamycin in combination with a calcineurin inhibitor to be detrimental in patients after SCT. 11 Interestingly, they observed-in line with our report-renal toxicity of rapamycin as three patients developed acute renal failure. 11 Therapeutically, it has been proven that concomitant application of an ACE-inhibitor or an angiotensin receptor blocker is beneficial in the setting of rapamycin-induced proteinuria not only in kidney transplant, 12 but also in heart transplant patients. 9 Therefore, we immediately started ACE-inhibitor treatment, which was found to be beneficial, even though it led to transient increase of serum creatinine (Figure 1 ). Nevertheless, we cannot exclude that ACE-inhibitor treatment without discontinuing rapamycin would have led to a comparable decrease in proteinuria.
Together, we provide evidence that rapamycin-induced proteinuria has also to be taken in account when starting rapamycin in allogenic stem cell-transplanted patients. Furthermore, we suggest starting rapamycin only when very limited or no proteinuria is evident. Abbreviations: GBM ¼ glomerular basement membrane; HPF ¼ high power field; MPO ¼ myeloperoxidase; Neg. ¼ negative; PR3 ¼ proteinase-3. Additional laboratory examinations evaluating the increase of proteinuria on the day of the presentation of the patient with nephrotic syndrome (03.07) are given.
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